Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial)

被引：9

作者：

Boiko A.N. ^{[1
,2
,3
,4
]}

Batysheva T.T. ^{[1
,2
,3
,4
]}

Minaeva N.G. ^{[1
,2
,3
,4
]}

Babina L.A. ^{[1
,2
,3
,4
]}

Vdovichenko T.V. ^{[1
,2
,3
,4
]}

Zhuravleva E.Y.U. ^{[1
,2
,3
,4
]}

Shikhkerimov R.K. ^{[1
,2
,3
,4
]}

Malykhina E.A. ^{[1
,2
,3
,4
]}

Khozova A.A. ^{[1
,2
,3
,4
]}

Zaitsev K.A. ^{[1
,2
,3
,4
]}

Kostenko E.V. ^{[1
,2
,3
,4
]}

机构：

[1] Department of Neurology and Neurosurgery, Russian State Medical University, Moscow

[2] Rehabilitation Polyclinic No. 7, Moscow

[3] Department of Nervous Diseases, Faculty of Therapy, Moscow State Medical-Dental University, Moscow

[4] Regional Neurological Department, Moscow Administrative Region

来源：

Neuroscience and Behavioral Physiology | 2008年 / 38卷 / 9期

关键词：

wearingoff"phenomenon; COMT; Constant dopaminergic stimulation; Entacapone; Fluctuation; Parkinson's disease; Stalevo;

D O I：

10.1007/s11055-008-9085-3

中图分类号：

学科分类号：

摘要：

Despite the significant symptomatic effects of levodopa, stable 24-h treatment responses are in the vast majority of patients replaced 2-3 years from the start of treatment by oscillations in motor symptoms (fluctuation, dyskinesia), amelioration of which requires addition of constant (physiological) stimulation of postsynaptic dopamine receptors. To some extent this is provided by Stalevo, which contains levodopa and two enzyme inhibitors: the DDC inhibitor carbidopa and the COMT inhibitor entacapone. The results obtained in the present study demonstrated the advantages of Stalevo over traditional agents in patients with the "wearing off" and "on-off" phenomena. © Springer Science+Business Media, Inc. 2008.

引用

页码：933 / 936

页数：3

共 22 条

[1]

Boiko A.N., Batysheva T.T., Chikina E.S., Et al., Experience in the use of dopamine receptor agonists in the out-patient treatment of Parkinson's disease, Zh. Nevrol. Psikhiat., 103, 9, pp. 54-58, (2003)

[2]

Boiko A.N., Batysheva T.T., Chikina E.S., Et al., Use of Tremonorm in Parkinson's disease: Experience of the out-patient neurological service of the Moscow City Health System, Zh. Nevrol. Psikhiat., 104, 12, pp. 23-28, (2004)

[3]

Boiko A.N., Batysheva T.T., Chikina E.S., Et al., Efficacy of PK-Merz in Parkinson's disease in out-patient practice, Lech. Nerv. Bolezn., 2, pp. 23-27, (2005)

[4]

Golubev V.L., Levin Ya.I., Vein A.M., Parkinson's Disease and Parkinson's Syndrome, (1999)

[5]

Golubev V.L., Palipovich A.A., New possibilities in the treatment of Parkinson's disease with Stalevo (levodopa/carbidopa/entacapone), Lech. Nerv. Bolezn., 1, pp. 1-11, (2006)

[6]

Levin O.S., Development of motor fluctuations in patients with different stages of Parkinson's disease, Atmosfera Nerv. Bolezn., 1, pp. 10-16, (2005)

[7]

Levin O.S., Fedorova N.V., Parkinson's Disease, (2006)

[8]

Fedorova N.V., Krivonos O.V., Chigir' I.P., Et al., Use of catechol-O-methyltransferase (COMT) inhibitors in the treatment of the late stages of Parkinson's disease, Kreml. Med., 2, pp. 66-72, (2001)

[9]

Fedorova N.V., Levin O.S., Smolentseva I.G., Et al., A new-generation levodopa preparation "Stalevo (levodopa/ carbidopa/entacapone), in the treatment of Parkinson's disease, Zh. Nevrol. Psikhiat., 9, pp. 39-46, (2006)

[10]

Shtok V.N., Fedorova N.V., Parkinson's Disease. Extrapyramidal Disorders. Handbook for Diagnosis and Treatment, pp. 87-124, (2002)

← 1 2 3 →